Department of Laboratory, Zibo Maternal and Child Health Hospital, Zibo, China.
Eur Rev Med Pharmacol Sci. 2020 Jun;24(12):6583-6588. doi: 10.26355/eurrev_202006_21643.
The purpose of this study was to detect the expression level of microRNA-210-3p (miRNA-210-3p) in cervical cancer (CC) tissues and its clinical significance.
Expression levels of miRNA-210-3p in collected CC tissues, normal cervical tissues and cervical intraepithelial neoplasia (CIN) tissues (CIN I, CIN II, and CIN III) were tested by reverse transcriptase-polymerase chain reaction (RT-PCR). The relationship between miRNA-210-3p level and clinical data of CC patients was analyzed. Moreover, the receiver operating characteristic (ROC) was introduced for assessing the diagnostic potential of miRNA-210-3p in CC.
Results revealed that miRNA-210-3p level was higher in CC tissues relative to normal cervical tissues and CIN tissues. Its expression was not correlated with age, pathological subtype, and tumor size of CC patients. However, miRNA-210-3p level was closely linked to FIGO stage, tumor differentiation, and lymphatic metastasis in CC. Based on depicted ROC, miRNA-210-3p was able to distinguish CC from normal cervical tissues and CIN tissues.
MiRNA-210-3p is upregulated in CC, and its level is closely correlated with FIGO stage, tumor differentiation, and lymphatic metastasis in CC patients. Besides, miRNA-210-3p produces a pronounced diagnostic efficacy, so it can be utilized as a novel hallmark for diagnosing CC and predicting the disease progression.
本研究旨在检测 microRNA-210-3p（miRNA-210-3p）在宫颈癌（CC）组织中的表达水平及其临床意义。
通过逆转录-聚合酶链反应（RT-PCR）检测收集的 CC 组织、正常宫颈组织和宫颈上皮内瘤变（CIN）组织（CIN I、CIN II 和 CIN III）中 miRNA-210-3p 的表达水平。分析 miRNA-210-3p 水平与 CC 患者临床数据之间的关系。此外，引入受试者工作特征（ROC）曲线评估 miRNA-210-3p 在 CC 中的诊断潜力。
结果表明，CC 组织中 miRNA-210-3p 水平高于正常宫颈组织和 CIN 组织。其表达与 CC 患者的年龄、病理亚型和肿瘤大小无关。然而，miRNA-210-3p 水平与 CC 的 FIGO 分期、肿瘤分化和淋巴转移密切相关。基于描绘的 ROC，miRNA-210-3p 能够区分 CC 与正常宫颈组织和 CIN 组织。
miRNA-210-3p 在 CC 中上调，其水平与 CC 患者的 FIGO 分期、肿瘤分化和淋巴转移密切相关。此外，miRNA-210-3p 具有显著的诊断效能，可作为诊断 CC 和预测疾病进展的新型标志物。
